Patents by Inventor Ana Laín Torre

Ana Laín Torre has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of ciclopirox as a modulator of the heme group biosynthesis and in the treatment of porphyrias and other diseases
    Patent number: 11337966
    Abstract: The present invention relates to the use of the compound ciclopirox or a pharmaceutically acceptable salt or solvate thereof for the treatment and/or prevention of a disease caused by dysregulated heme group biosynthesis, with the proviso that said disease is not congenital erythropoietic porphyria.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: May 24, 2022
    Assignee: ASOCIACIÓN CENTRO DE INVESTIGACIÓN COOPERATIVA EN BIOCIENCIAS-CIC BIOGUNE
    Inventors: Oscar Millet Aguilar-Galindo, Arantza Sanz Parra, Ana Laín Torre, Pedro David Urquiza Ortiz, Juan Manuel Falcón Pérez, Joaquín Castilla Castrillón, Itxaso San Juan Quintana, Ganeko Bernardo-Seisdedos
  • USE OF CICLOPIROX AS A MODULATOR OF THE HEME GROUP BIOSYNTHESIS AND IN THE TREATMENT OF PORPHYRIAS AND OTHER DISEASES
    Publication number: 20200171013
    Abstract: The present invention relates to the use of the compound ciclopirox or a pharmaceutically acceptable salt or solvate thereof for the treatment and/or prevention of a disease caused by dysregulated heme group biosynthesis, with the proviso that said disease is not congenital erythropoietic porphyria.
    Type: Application
    Filed: April 27, 2018
    Publication date: June 4, 2020
    Inventors: Oscar MILLET AGUILAR-GALINDO, Arantza SANZ PARRA, Ana LAÍN TORRE, Pedro David URQUIZA ORTIZ, Juan Manuel FALCÓN PÉREZ, Joaquín CASTILLA CASTRILLÓN, Itxaso SAN JUAN QUINTANA, Ganeko BERNARDO-SEISDEDOS
  • Use of ciclopirox for the treatment of congenital erythropoietic porphyria
    Patent number: 10420755
    Abstract: The present invention relates to the use of the compound ciclopirox or a pharmaceutically acceptable salt or solvate thereof for the treatment and/or prevention of congenital erythropoietic porphyria (CEP).
    Type: Grant
    Filed: October 27, 2017
    Date of Patent: September 24, 2019
    Assignee: ASOCIACIÓN CENTRO DE INVESTIGACIÓN COOPERATIVA EN BIOCIENCIAS-CIC BIOGUNE
    Inventors: Oscar Millet Aguilar-Galindo, Arantza Sanz Parra, Ana Laín Torre, Pedro David Urquiza Ortiz, Juan Manuel Falcón Pérez
  • USE OF CICLOPIROX FOR THE TREATMENT OF CONGENITAL ERYTHROPOIETIC PORPHYRIA
    Publication number: 20190183871
    Abstract: The present invention relates to the use of the compound ciclopirox or a pharmaceutically acceptable salt or solvate thereof for the treatment and/or prevention of congenital erythropoietic porphyria (CEP).
    Type: Application
    Filed: October 27, 2017
    Publication date: June 20, 2019
    Inventors: Oscar MILLET AGUILAR-GALINDO, Arantza SANZ PARRA, Ana LAÍN TORRE, Pedro David URQUIZA ORTIZ, Juan Manuel FALCÓN PÉREZ
  • Use of inhibitors of porphobilinogen deaminase in the treatment of congenital erythropoietic porphyria
    Patent number: 9138423
    Abstract: The invention relates to the use of a compound of general formula (I), wherein R1 and R2 are independently H or C1-C6 alkyl, or R1 and R2 are bound to one another forming an optionally substituted fused benzene ring, R3 is H, C1-C6 alkyl or —CH2— CH(NH2)—COOH and R4 is H, C1-C6 alkyl, or R4 represents (II) or (III) in the preparation of a medicinal product for treating and/or preventing congenital erythropoietic porphyria (CEP).
    Type: Grant
    Filed: August 5, 2011
    Date of Patent: September 22, 2015
    Assignee: Asociación Centro de Investigación Cooperativa en Biociencias—CIC Biogune
    Inventors: Oscar Millet Aguilar-Galindo, Ana Laín Torre
  • USE OF INHIBITORS OF PORPHOBILINOGEN DEAMINASE IN THE TREATMENT OF CONGENITAL ERYTHROPOIETIC PORPHYRIA
    Publication number: 20130172397
    Abstract: The invention relates to the use of a compound of general formula (I), wherein R1 and R2 are independently H or C1-C6 alkyl, or R1 and R2 are bound to one another forming an optionally substituted fused benzene ring, R3 is H, C1-C6 alkyl or —CH2—CH(NH2)—COOH and R4 is H, C1-C6 alkyl, or R4 represents (II) or (III) in the preparation of a medicinal product for treating and/or preventing congenital erythropoietic porphyria (CEP).
    Type: Application
    Filed: August 5, 2011
    Publication date: July 4, 2013
    Applicant: CENTRO DE INVESTIGACIÓN COOPERATIVA EN BIOCIENCIAS-CIC bioGUNE
    Inventors: Oscar Millet Aguilar-Galindo, Ana Laín Torre